At the news
? BULLISHIMPACT 6/10 8-K filed Aug 31, 2026 at 06:01 ET
BioMarin entered a binding term sheet with Ascendis Pharma to settle all global patent litigation. Ascendis will pay BioMarin a royalty of 20% of net sales of Yuviwel in the U.S. (retroactive to first commercial sale) and 18% in the EU, Brazil, and South Korea until May 2030. The deal removes legal overhang and establishes a long-term revenue stream tied to Ascendis's achondroplasia product, but no upfront payment or near-term revenue guidance was provided.
- BioMarin entered a binding term sheet with Ascendis Pharma resolving all global patent litigation, including an ITC Section 337 investigation.
- Ascendis will pay a royalty of 20% of annual net sales of Yuviwel in the U.S. and 18% in the EU, Brazil, and South Korea until May 2030.
- Royalties are retroactive to the date of first commercial sale in each territory.
- The license covers Yuviwel for all current and potential indications, including achondroplasia and hypochondroplasia, and combination therapies.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access